JMS-17-2 是一种有效的选择性 CX3CR1 拮抗剂，IC50 为 0.32 nM。JMS-17-2 降低乳腺癌细胞的转移和定植。
货号:ajcx38726
CAS:1380392-05-1
分子式:C25H26ClN3O
分子量：419.95
溶解度:DMSO : 25 mg/mL (59.53 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存： 现货

Background:

JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells[1].

JMS-17-2 (10 mg/kg; aministered i.p.; twice a day for three weeks) causes a dramatic reduction of tumors in both skeleton and visceral organs in SCID mice[1].

[1]. Shen F, et al. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14(6):518-27.